Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 6/2018

10.11.2017 | Original Paper

Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort

verfasst von: G. Fond, N. Resseguier, F. Schürhoff, O. Godin, M. Andrianarisoa, L. Brunel, E. Bulzacka, B. Aouizerate, F. Berna, D. Capdevielle, I. Chereau, T. D’Amato, C. Dubertret, J. Dubreucq, C. Faget, F. Gabayet, C. Lançon, P. M. Llorca, J. Mallet, D. Misdrahi, C. Passerieux, R. Rey, A. Schandrin, M. Urbach, P. Vidailhet, L. Boyer, M. Leboyer, the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Low-grade inflammation has repeatedly been associated with schizophrenia (SZ) and in particular with cognitive impairment. Female gender, overweight and tobacco smoking have been suggested as risk factors to increase inflammation while preclinical inconsistent findings have been found regarding the association with psychotropic drugs. The aim of this study was to explore if psychotropic drugs were associated with inflammation in SZ and to determine which psychotropic drug was associated with inflammation in stable SZ subjects while considering clinical confounding factors. Participants were consecutively included in the network of the FondaMental Expert Centers for Schizophrenia and received a thorough clinical assessment, including recording of current treatment. High-sensitivity CRP (hs-CRP) was measured for each participant as a proxy to define peripheral low-grade inflammation. The zero-inflated Poisson regression model estimated the relationship between low-grade inflammation and psychotropic drug. Four hundred and five stabilized, community-dwelling SZ subjects (mean age = 32.6 years, 74% male gender) have been included. In total, 148 participants (36.5%) were found with undetectable blood hs-CRP level. The probability of having an undetectable CRP was associated with a lower body mass index (p < 0.0001) and no cyamemazine add-on antipsychotic therapy (p = 0.001). The other 257 participants (63.5%) were found to have low-grade inflammation (hs-CRP > 0 mg/L). Low-grade inflammation was significantly associated with female gender (p = 0.004), higher body mass index (p < 0.0001), current tobacco smoking (p < 0.0001), clomipramine (p = 0.04), quetiapine (p < 0.0001) and hypnotic (p = 0.0006) consumption while decreased hs-CRP blood levels was associated with aripiprazole (p = 0.004) and valproate/valpromide (p = 0.03) consumption. The present study suggests that some psychotropic drugs (quetiapine, cyamemazine, clomipramine) may be associated with increased peripheral low-grade inflammation in SZ patients while others (aripiprazole, valproate) may be associated with decreased peripheral low-grade inflammation. These results should be replicated in SZ and non-SZ populations and the biological underpinnings should be further explored.
Literatur
1.
Zurück zum Zitat Strawbridge R, Arnone D, Danese A et al (2015) Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 25:1532–1543CrossRefPubMed Strawbridge R, Arnone D, Danese A et al (2015) Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 25:1532–1543CrossRefPubMed
3.
Zurück zum Zitat Dickerson F, Stallings C, Origoni A et al (2013) Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 150:456–459CrossRefPubMed Dickerson F, Stallings C, Origoni A et al (2013) Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 150:456–459CrossRefPubMed
11.
Zurück zum Zitat Sommer IE, van Westrhenen R, Begemann MJ et al (2013) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40:181–191 (sbt139) CrossRefPubMedPubMedCentral Sommer IE, van Westrhenen R, Begemann MJ et al (2013) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40:181–191 (sbt139) CrossRefPubMedPubMedCentral
13.
18.
Zurück zum Zitat Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671CrossRefPubMedPubMedCentral Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Hannestad J, DellaGioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:2452–2459CrossRefPubMedPubMedCentral Hannestad J, DellaGioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36:2452–2459CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Maes M, Bosmans E, Calabrese J et al (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29:141–152CrossRefPubMed Maes M, Bosmans E, Calabrese J et al (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29:141–152CrossRefPubMed
35.
Zurück zum Zitat Miller BJ, Culpepper N, Rapaport MH (2014) C-reactive protein levels in schizophrenia. Clin Schizophr Relat Psychoses 7:223–230CrossRefPubMed Miller BJ, Culpepper N, Rapaport MH (2014) C-reactive protein levels in schizophrenia. Clin Schizophr Relat Psychoses 7:223–230CrossRefPubMed
36.
Zurück zum Zitat MacCallum RC, Zhang S, Preacher KJ, Rucker DD (2002) On the practice of dichotomization of quantitative variables. Psychol Methods 7:19–40CrossRefPubMed MacCallum RC, Zhang S, Preacher KJ, Rucker DD (2002) On the practice of dichotomization of quantitative variables. Psychol Methods 7:19–40CrossRefPubMed
42.
Zurück zum Zitat Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276CrossRefPubMed Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276CrossRefPubMed
51.
Zurück zum Zitat Zoppi G, Cinquetti M, Luciano A et al (1992) The intestinal ecosystem in chronic functional constipation. Acta Paediatr Oslo Nor 1992 87:836–841 Zoppi G, Cinquetti M, Luciano A et al (1992) The intestinal ecosystem in chronic functional constipation. Acta Paediatr Oslo Nor 1992 87:836–841
70.
Zurück zum Zitat Kim JH, Cho HT, Kim YJ (2014) The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation. Endocr J 61:1055–1067CrossRefPubMed Kim JH, Cho HT, Kim YJ (2014) The role of estrogen in adipose tissue metabolism: insights into glucose homeostasis regulation. Endocr J 61:1055–1067CrossRefPubMed
71.
Zurück zum Zitat Li X, Zhang J, Zhu X et al (2015) Progesterone reduces inflammation and apoptosis in neonatal rats with hypoxic ischemic brain damage through the PI3K/Akt pathway. Int J Clin Exp Med 8:8197–8203PubMedPubMedCentral Li X, Zhang J, Zhu X et al (2015) Progesterone reduces inflammation and apoptosis in neonatal rats with hypoxic ischemic brain damage through the PI3K/Akt pathway. Int J Clin Exp Med 8:8197–8203PubMedPubMedCentral
Metadaten
Titel
Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort
verfasst von
G. Fond
N. Resseguier
F. Schürhoff
O. Godin
M. Andrianarisoa
L. Brunel
E. Bulzacka
B. Aouizerate
F. Berna
D. Capdevielle
I. Chereau
T. D’Amato
C. Dubertret
J. Dubreucq
C. Faget
F. Gabayet
C. Lançon
P. M. Llorca
J. Mallet
D. Misdrahi
C. Passerieux
R. Rey
A. Schandrin
M. Urbach
P. Vidailhet
L. Boyer
M. Leboyer
the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group
Publikationsdatum
10.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 6/2018
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-017-0847-1

Weitere Artikel der Ausgabe 6/2018

European Archives of Psychiatry and Clinical Neuroscience 6/2018 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.